Sinqi Pharmaceutical (300573) said in an agency conference call a few days ago that after 0.01% atropine sulfate eye drops were approved, the production line began 24-hour uninterrupted production to meet the market demand of the product. Currently, the production line is running smoothly and production continues in compliance. Recently, products produced by the company's new production lines have been put on the market one after another. In the future, the company will expand production capacity in advance according to changes in market demand to fully meet market demand.
兴齐眼药：在0.01%硫酸阿托品滴眼液获批后，生产线就24小时不间断生产
Sinqi Pharmaceutical: After 0.01% atropine sulfate eye drops were approved, the production line was uninterrupted for 24 hours
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.